Indaptus Therapeutics reduces warrant exercise prices to $1.75; enters voting agreements ahead of special meeting

Indaptus Therapeutics, Inc.

Company repriced ~913,638 warrants held by certain holders from $8.30-$47.60 down to $1.75.
Board unilaterally reduced exercise prices of remaining ~762,787 warrants to $1.75.
Holders agreed to vote shares in favor of proposals at Feb 26, 2026 special meeting.
New exercise price of $1.75 equals Nasdaq Minimum Price per applicable rules.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Indaptus Therapeutics, Inc. entered into Repricing Agreements with Executing Holders (effective 2026-02-11).

Action: entry
Counterparty: Executing Holders
Effective: 2026-02-11

Exact text from the filing

On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”).

View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-006330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.